Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SHPH | 8-K | bearish | 7/10 | Shuttle Pharmaceuticals entered into a merger agreement with United Dogecoin Inc., a dogecoin mining company, and concur | May 1, 2026 |
| VXRT | PRESS-RELEASE | bearish | 7/10 | Vaxart reported a significant Q4 2025 EPS miss of -$0.10 versus the $0.02 consensus, a 600% negative surprise. No revenu | May 1, 2026 |
| AMTX | PRESS-RELEASE | neutral | 1/10 | Aemetis, Inc. announced it will report its Q1 2026 results on May 7, 2026. | May 1, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced its participation in the Digestive Disease Week (DDW) 2026 annual meeting, including a | May 1, 2026 |
| IFRX | PRESS-RELEASE | neutral | 1/10 | InflaRx N.V. announced it will report its Q1 2026 results on May 7, 2026. | May 1, 2026 |
| AXSM | PRESS-RELEASE | bullish | 8/10 | Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's disease dementia, a maj | May 1, 2026 |
| ESPR | PRESS-RELEASE | bullish | 7/10 | Esperion has agreed to be acquired by ARCHIMED for $3.16 per share in cash at closing, plus contingent milestone payment | May 1, 2026 |
| MPLT | PRESS-RELEASE | neutral | 4/10 | MapLight Therapeutics announced completion of enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia (30 | May 1, 2026 |
| MOLN | PRESS-RELEASE | neutral | 4/10 | Molecular Partners announced publication of Phase 1 data for MP0317, a tumor-localized CD40 agonist, in Nature Cancer. T | May 1, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals received European Commission approval for IMCIVREE (setmelanotide) to treat acquired hypothalamic | May 1, 2026 |
| LYB | PRESS-RELEASE | mixed | 6/10 | LyondellBasell reported Q1 2026 GAAP EPS of $0.38 (vs consensus $0.28, beat) but GAAP net income of $125M was down 29% Y | May 1, 2026 |
| LYB | PRESS-RELEASE | neutral | 4/10 | LyondellBasell completed the sale of select European olefins and polyolefins assets to AEQUITA, a key step in its Europe | May 1, 2026 |
| SPTX | 3 | neutral | 2/10 | CEO Daphne Zohar and director Sandra E. Peterson filed initial beneficial ownership statements (Form 3) for Seaport Ther | Apr 30, 2026 |
| SPTX | 3 | neutral | 2/10 | Three insiders at Seaport Therapeutics (SPTX), CFO Lauren White, director Denice Torres, and director Sharon Mates, file | Apr 30, 2026 |
| SPTX | 3 | neutral | 2/10 | Jason Pitts, Ph.D., filed a Form 3 initial statement of beneficial ownership upon becoming a director of Seaport Therape | Apr 30, 2026 |
| SPTX | 3 | neutral | 2/10 | Three directors of Seaport Therapeutics (SPTX) filed initial statements of beneficial ownership (Form 3) on April 30, 20 | Apr 30, 2026 |
| SPTX | 3 | neutral | 2/10 | Two initial statements of beneficial ownership (Form 3) were filed for Seaport Therapeutics (SPTX) by incoming officer A | Apr 30, 2026 |
| RNTX | PRESS-RELEASE | bearish | 8/10 | Rein Therapeutics priced a $50M underwritten public offering of 50M shares at $1.00/share, with an underwriter option fo | Apr 30, 2026 |
| GEVO | CLUSTER | neutral | 2/10 | Two GEVO insiders, including the President & COO, sold a combined $103K in shares over a one-week window. The sales repr | Apr 30, 2026 |
| HELP | PRESS-RELEASE | neutral | 3/10 | Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major dep | Apr 30, 2026 |
| COAG | PRESS-RELEASE | neutral | 5/10 | Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an un | Apr 30, 2026 |
| COAG | 3 | neutral | 3/10 | Novo Holdings A/S filed a Form 3 initial statement of beneficial ownership, disclosing holdings in Hemab Therapeutics (C | Apr 30, 2026 |
| COAG | 3 | neutral | 3/10 | RA Capital Management and affiliated entities filed Form 3 initial statements of beneficial ownership for Hemab Therapeu | Apr 30, 2026 |
| KNSA | CLUSTER | neutral | 3/10 | Kiniksa Pharmaceuticals CEO Sanj K. Patel and Director Barry D. Quart sold a combined $4.42M in open-market shares on Ap | Apr 30, 2026 |
| COAG | 3 | neutral | 2/10 | John Michael Maraganore filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his holding | Apr 30, 2026 |
| COAG | 3 | neutral | 2/10 | Linda Catharina Bain filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing her holdings in H | Apr 30, 2026 |
| COAG | 3 | neutral | 2/10 | Laura Tadvalkar filed a Form 3 initial statement of beneficial ownership with Hemab Therapeutics Holdings, Inc. (COAG), | Apr 30, 2026 |
| COAG | 3 | neutral | 2/10 | Two insiders at Hemab Therapeutics (COAG) filed initial statements of beneficial ownership (Form 3) on April 30, 2026, d | Apr 30, 2026 |
| COAG | 3 | neutral | 2/10 | Benny Sorensen, the President and CEO of Hemab Therapeutics, filed an initial Form 3 disclosing beneficial ownership of | Apr 30, 2026 |
| INCR | PRESS-RELEASE | mixed | 6/10 | InterCure reported FY2025 revenue of NIS 270M (+13% YoY), a net loss of NIS 37M (improved from NIS 73M loss in 2024), an | Apr 30, 2026 |